Transvaginal pelvic ultrasound
 

Transvaginal pelvic ultrasound

Back to Top

Exam Overview

Transvaginal pelvic ultrasound is a test that uses reflected sound waves to produce a picture of the uterus and other structures inside the pelvis. It does not use X-rays or other types of radiation.

A small ultrasound device (transducer) is inserted into the vagina. High-pitched sound waves emitted from the transducer bounce off the uterus and ovaries. The sound waves send out high-pitched sounds (above the range of human hearing) that are reflected back to the transducer. A microphone analyzes the sound waves and converts them into a picture that is displayed on a video monitor. The picture produced by ultrasound is called a sonogram, echogram, or scan.

Back to Top

Why It Is Done

Transvaginal ultrasound is used to evaluate women with dysfunctional uterine bleeding and to determine whether an abnormal area (such as an endometrial polyp or uterine fibroid) is present in the uterus before hysteroscopy is performed. In postmenopausal women, the thickness of the uterine lining is evaluated to check for overgrowth (hyperplasia) or cancer of the lining of the uterus (endometrium). If no abnormal areas are found, a hysteroscopy or an endometrial biopsy may not need to be performed.

After the pelvic exam, a transvaginal ultrasound is often the next step in diagnosing dysfunctional uterine bleeding.

Back to Top

Results

Ultrasound results may be normal or abnormal.

Normal

No abnormal areas are found in the uterus.

Ultrasound may not detect small lesions (less than 1 inch or 2.5 cm). The likelihood of finding smaller lesions is improved if 10 to 15 mL of fluid is placed in the uterus before the exam (sonohysterography).1

Abnormal

An abnormal area (lesion) is found.

Back to Top

What To Think About

A treatment plan can be developed based on the results of the pelvic exam and ultrasound. Knowing the size, number, and location of lesions helps determine:

  • Which treatment method might be most successful.
  • Which surgical method is most appropriate to control dysfunctional uterine bleeding.

If bleeding is severe and fertility is a concern, hysteroscopy or laparoscopy may be needed to determine a treatment plan. See Exams and Tests.

Complete the medical test information form (PDF)Click here to view a form.(What is a PDF document?) to help you prepare for this test.

Back to Top

References

Citations

  1. Mishell DR Jr, et al. (2001). Abnormal uterine bleeding. In MA Stenchever et al., eds., Comprehensive Gynecology, 4th ed., pp. 1079–1097. St. Louis: Mosby.

Back to Top

Credits

AuthorKathe Gallagher, MSW
AuthorDebby Golonka, MPH
EditorKathleen M. Ariss, MS
EditorSusan Van Houten, RN, BSN, MBA
Associate EditorPat Truman
Primary Medical ReviewerKathleen Romito, MD
- Family Medicine
Specialist Medical ReviewerLiisa Honey, MD, FRCSC
- Obstetrics and Gynecology
Last UpdatedFebruary 22, 2006
Latest Cancer News
Zevalin® Confirmed Effective for Patients with Follicular Lymphoma Who Have Failed an Autologous Transplant

September 5, 2008 — Researchers from France have reported that five of eight patients with follicular lymphoma who had failed an autologous stem cell transplant achieved a complete remission with standard doses of Zevalin® (Yttrium-90 ((90)Y) ibritumomab tiuxetan). The details of this study appeared in an early online publication in Leukemia-Lymphoma of July 15, 2008.

Forty Percent of Postmenopausal Breast Cancers Preventable by Lifestyle Changes

September 5, 2008 — Researchers from the University of Wisconsin-Madison, the H. Lee Moffitt Cancer Center, Dartmouth Medical School, and the Fred Hutchinson Cancer Center have reported that 40.7% of postmenopausal breast cancer can be prevented by changes in lifestyle. The details of this study appeared in the August 15, 2008 issue of the American Journal of Epidemiology.

US FDA lists drugs under safety probes

September 5, 2008 — WASHINGTON (Reuters) - U.S. health officials said on Friday they are probing safety concerns with Eli Lilly and Co's antidepressant Cymbalta, Biogen Idec and Elan Corp's multiple sclerosis drug Tysabri and more than a dozen other medicines.

Select news items provided by Reuters Health